Lotronex (TM): therapy for diarrhea predominant irritable bowel syndrome
Record ID 32001000068
To summarise the available evidence on Lotronex (TM) for diarrhea predominant irritable bowel syndrome (IBS).
Authors' recomendations: Lotronex (TM) has been approved for marketing in the United States for the treatment of IBS in women whose predominant symptom is diarrhea. Lotronex (TM) has not yet been approved for marketing in Canada. In most cases, IBS can be managed successfully without drugs. Current treatment for IBS include education, reassurance and diet. While participants in clinical trials have reported improvements in a number of symptoms when taking Lotronex (TM), these trials have also shown a very high placebo response rate. Some patients receiving Lotronex (TM) in the USA have reported serious adverse effects, including surgical complications of constipation, ischemic colitis and liver toxicity.
Authors' methods: Overview
Project Status: Completed
URL for project: https://www.ccohta.ca/research/index.html
Year Published: 2000
English language abstract: An English language summary is available
Publication Type: Not Assigned
- Serotonin Antagonists
- Colonic Diseases, Functional
Organisation Name: Canadian Coordinating Office for Health Technology Assessment
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name: firstname.lastname@example.org
Contact Email: email@example.com
Copyright: Canadian Coordinating Office for Health Technology Assessment
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.